EGS manufactures EsophyX technology is used to reconstruct the gastroesophageal valve in the TIF 2.0 procedure.
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 6, 2022 | Series Unknown | $18M | — | — | — | Detail |
Nov 25, 2020 | Series Unknown | $27M | 1 | Vertex Growth Fund | — | Detail |
May 28, 2019 | Series I | $15M | 1 | Accelmed | — | Detail |
Jun 19, 2018 | Series I | $40.64M | 7 | Advanced Technology Ventures | — | Detail |
Dec 1, 2015 | Series Unknown | $50M | 6 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Vertex Growth Fund | Yes | Series Unknown |
Accelmed | Yes | Series I |
Advanced Technology Ventures | Yes | Series I |
Canaan Partners | — | Series I |
Chicago Growth Partners | — | Series I |
CRG | — | Series I |
Evidity Health Capital | — | Series I |
Radius Ventures | — | Series I |
SightLine Partners | — | Series I |
Foundation Medical Partners | — | Series Unknown |